ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Acer Pharma Limited

Acer Pharma Limited is an active company incorporated on 7 March 2016 with the registered office located in Walsall, West Midlands. Acer Pharma Limited was registered 9 years ago.
Status
Active
Active since incorporation
Company No
10045381
Private limited company
Age
9 years
Incorporated 7 March 2016
Size
Micro
Turnover is under £1M
Under 10 employees
Confirmation
Submitted
Dated 6 March 2025 (8 months ago)
Next confirmation dated 6 March 2026
Due by 20 March 2026 (4 months remaining)
Last change occurred 7 months ago
Accounts
Submitted
For period 1 Apr31 Mar 2024 (1 year)
Accounts type is Total Exemption Full
Next accounts for period 30 April 2025
Due by 31 January 2026 (2 months remaining)
Address
Units 5-7 Tintagel Way
Aldridge
Walsall
WS9 8ER
England
Same address for the past 4 years
Telephone
Unreported
Email
Unreported
People
Officers
2
Shareholders
1
Controllers (PSC)
1
PSC • Director • British • Lives in England • Born in Jun 1973
Director • British • Lives in England • Born in Dec 1969
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
C. S. T. Pharma Limited
Jason Derick Yates and Ian Pritchard are mutual people.
Active
MPT Pharma Limited
Jason Derick Yates and Ian Pritchard are mutual people.
Active
UTH Aesthetics Limited
Ian Pritchard and Jason Derick Yates are mutual people.
Active
Acre Medical Limited
Ian Pritchard and Jason Derick Yates are mutual people.
Active
C.S.T. Pharma Group Holdings Limited
Ian Pritchard and Jason Derick Yates are mutual people.
Active
Acre Aesthetics Limited
Ian Pritchard and Jason Derick Yates are mutual people.
Active
Synertech Ltd
Ian Pritchard and Jason Derick Yates are mutual people.
Active
Curagenix Life Sciences Limited
Ian Pritchard and Jason Derick Yates are mutual people.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2017–2024)
Period Ended
31 Mar 2024
For period 31 Mar31 Mar 2024
Traded for 12 months
Cash in Bank
£3.18K
Increased by £491 (+18%)
Turnover
Unreported
Same as previous period
Employees
2
Increased by 2 (%)
Total Assets
£3.2M
Decreased by £1.56M (-33%)
Total Liabilities
-£798.03K
Decreased by £297.63K (-27%)
Net Assets
£2.4M
Decreased by £1.27M (-35%)
Debt Ratio (%)
25%
Increased by 1.93% (+8%)
Latest Activity
Confirmation Submitted
7 Months Ago on 26 Mar 2025
Full Accounts Submitted
11 Months Ago on 4 Dec 2024
Accounting Period Extended
1 Year 4 Months Ago on 4 Jul 2024
New Charge Registered
1 Year 4 Months Ago on 26 Jun 2024
Confirmation Submitted
1 Year 7 Months Ago on 8 Apr 2024
Full Accounts Submitted
1 Year 10 Months Ago on 19 Dec 2023
Mr Ian Pritchard Appointed
2 Years Ago on 29 Oct 2023
Michelle Grenan Resigned
2 Years 4 Months Ago on 22 Jun 2023
Confirmation Submitted
2 Years 7 Months Ago on 20 Mar 2023
Full Accounts Submitted
2 Years 10 Months Ago on 19 Dec 2022
Get Credit Report
Discover Acer Pharma Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Confirmation statement made on 6 March 2025 with updates
Submitted on 26 Mar 2025
Total exemption full accounts made up to 31 March 2024
Submitted on 4 Dec 2024
Current accounting period extended from 31 March 2025 to 30 April 2025
Submitted on 4 Jul 2024
Registration of charge 100453810006, created on 26 June 2024
Submitted on 2 Jul 2024
Confirmation statement made on 6 March 2024 with no updates
Submitted on 8 Apr 2024
Total exemption full accounts made up to 31 March 2023
Submitted on 19 Dec 2023
Appointment of Mr Ian Pritchard as a director on 29 October 2023
Submitted on 8 Nov 2023
Termination of appointment of Michelle Grenan as a director on 22 June 2023
Submitted on 22 Jun 2023
Confirmation statement made on 6 March 2023 with no updates
Submitted on 20 Mar 2023
Total exemption full accounts made up to 31 March 2022
Submitted on 19 Dec 2022
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year